Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor

J Biol Chem. 1988 Nov 5;263(31):15845-8.

Abstract

To identify factors potentially influencing expression of type 1 plasminogen activator inhibitor (PAI-1), we characterized the human tissue-specific distribution of PAI-1 mRNA and the influence of epidermal growth factor (EGF) on expression of steady state levels of PAI-1 mRNA and secretion of PAI-1 by Hep G2 cells. Two species of PAI-1 mRNA (3.2 and 2.2 kilobases) were detected, and the ratio of the two varied among tissues (3 to 5:1) in contrast to the 1:1 ratio detected in Hep G2 cells. Expression of PAI-1 mRNA was inversely related to the distribution of tissue-type plasminogen activator mRNA (2.3 kilobases). Nu-Serum, a growth media supplement, increased steady state levels of PAI-1 mRNA 5-fold within 3 h. Factors responsible were found to be trypsin-sensitive and dialysis-resistant. Antisera to EGF attenuated Nu-Serum-induced increases of PAI-1 mRNA by 57%, suggesting that EGF or EGF homologous peptides contributed to the response. EGF elicited increases of PAI-1 mRNA levels in a dose-dependent manner. Induction was rapid (7-fold at 3 h with 5 ng/ml) and complete within 10 h. The response was not attenuated by cycloheximide (25 micrograms/ml). Factor X and glyceraldehyde-3-phosphate dehydrogenase mRNA did not increase. Increased levels of PAI-1 antigen were detected in conditioned media of Hep G2 cells by 4 h and were maximal at 8 h (6-fold). We conclude that the expression of PAI-1 mRNA is tissue-specific and regulated by epidermal growth factor in Hep G2 cells.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Carcinoma, Hepatocellular
  • Cell Line
  • Epidermal Growth Factor / pharmacology*
  • Factor X / genetics
  • Female
  • Gene Expression Regulation / drug effects*
  • Glyceraldehyde-3-Phosphate Dehydrogenases / genetics
  • Glycoproteins / biosynthesis
  • Glycoproteins / genetics*
  • Glycoproteins / metabolism
  • Humans
  • Kinetics
  • Liver Neoplasms
  • Organ Specificity
  • Plasminogen Activators / antagonists & inhibitors
  • Plasminogen Inactivators
  • RNA, Messenger / drug effects
  • RNA, Messenger / genetics*
  • Transcription, Genetic / drug effects*

Substances

  • Glycoproteins
  • Plasminogen Inactivators
  • RNA, Messenger
  • Epidermal Growth Factor
  • Factor X
  • Glyceraldehyde-3-Phosphate Dehydrogenases
  • Plasminogen Activators